Clik here to view.
Dr. Grant Stevens to Speak at 37th Annual ASAPS Conference, Tasmania
MARINA DEL REY, Calif. Grant Stevens, M.D., FACS, a board certified plastic surgeon, founder of Marina Plastic Surgery in Marina del Rey, CA, and an international traveling professor, is a featured...
View ArticleClik here to view.
Seegene to Unveil at AACC 2014 the Innovative Real-Time PCR Technology That...
GAITHERSBURG, Md. & SEOUL, South Korea Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, today announced “MuDT™” technology, the industry’s first real-time PCR...
View ArticleClik here to view.
ONCODESIGN: 1st Half of 2014
DIJON, France ONCODESIGN, a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known...
View ArticleClik here to view.
Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal...
CAMBRIDGE, England Biosceptre, the oncology company developing antibody products that target the nf-P2X7 receptor, announces positive results from its Phase I trial to assess the safety and...
View ArticleClik here to view.
Dr. Reddy’s to Release Q1 FY15 Results on July 30, 2014
HYDERABAD, India Dr. Reddy’s Laboratories (NYSE: RDY) will announce results for the First Quarter ended June 30, 2014 on Wednesday, July 30, 2014 after the Board Meeting. The results will be...
View ArticleClik here to view.
エリテック、米国にて急性リンパ芽球性白血病を対象に ERY-ASPを検討する第 I/II 相試験で、初の患者組み入れを発表
仏リヨン （ビジネスワイヤ） — 急性白血病および医療ニーズが満たされていないその他の腫瘍適応症を対象に革新的な「腫瘍飢餓化」治療薬の開発に当たっているフランスのバイオ製薬企業エリテック・ファーマ（Paris:ERYP）（Euronext Paris: FR0011471135 – ERYP）は、米国にて急性リンパ芽球性白血病を対象に ERY-ASPを検討する第 I/II...
View ArticleClik here to view.
Personalized Chemotherapy Tests Cleared for Use in China
SHANGHAI & BETHLEHEM, Pa. Fosun Diagnostics, a division of Fosun Pharmaceuticals, and Saladax Biomedical, Inc. today announced the launch of the MyCare™ portfolio of exposure optimization tests...
View ArticleClik here to view.
Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. Announce Strategic...
NEW YORK & OSAKA, Japan Bristol-Myers Squibb Company (NYSE:BMY) and Ono Pharmaceutical Co., Ltd. (“Ono”) have signed a strategic collaboration agreement to jointly develop and commercialize...
View ArticleClik here to view.
The Best Heart Disease Treatment in Thailand at Phyathai Nawamin...
BANGKOK Heart disease is a very common disease of the world population. It’s 1 in 4 of the cause of death all nationalities and countries. Heart disease can find in all age from newborns to the...
View ArticleClik here to view.
FOVE, the World’s First Eye Tracking Head Mount Display! Aiming for Global...
TOKYO On July 23rd FOVE, Inc. announced its development of the world’s first consumer orientated eye tracking head mount display along with our first teaser movie (fove-inc.com). FOVE has completed...
View ArticleClik here to view.
CANbridge Life Sciences And EUSA Pharma Form Agreement to Commericalize...
BEIJING CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has entered into an exclusive partnership with EUSA Pharma, a Jazz...
View ArticleClik here to view.
Wearable Device for the Early Detection of Common Diabetes-related...
WASHINGTON A group of researchers in Taiwan has developed a new optical technology that may be able to detect an early complication of diabetes sooner, when it is more easily treated. If the device...
View ArticleClik here to view.
ERYTECH Announces Enrollment of First Patient in Phase II Study of ERY-ASP in...
LYON, France Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 – ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute...
View ArticleClik here to view.
Hoya Announces First Quarter Financial Results
TOKYO HOYA Corporation (TOKYO:7741) today announced financial results for the first quarter ended June 30, 2014. For the quarter under review, group sales increased 12.6% to 113,071 million yen...
View ArticleClik here to view.
エリテックがすい臓がんでERY-ASPを検討する第II相試験で最初の患者組み入れを発表
仏リヨン （ビジネスワイヤ） — 急性白血病および医療ニーズが満たされていないその他の腫瘍適応症を対象に革新的な「腫瘍飢餓化」治療薬の開発に当たっているフランスのバイオ製薬企業エリテック・ファーマ（Paris:ERYP）（Euronext Paris: FR0011471135 –...
View ArticleClik here to view.
Harlan Provides Expertise for Biologics and Biosimilars
ITINGEN, Switzerland Harlan Laboratories, Ltd., a privately held provider of general and specialty toxicology services through its Contract Research Services (CRS) business, is prepared to meet the...
View ArticleClik here to view.
Dr. Reddy’s Q1 FY15 Financial Results
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced its unaudited consolidated financial results for the quarter ended June 30, 2014 under International Financial Reporting...
View ArticleClik here to view.
Zoll Receives Shonin Approval from Japanese Ministry of Health, Labour and...
CHELMSFORD, Mass. ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that its Japanese subsidiary, Asahi Kasei ZOLL Medical (AZM), has...
View ArticleClik here to view.
Harlan提供生物制剂和生物类似物领域的专项技能
瑞士伊廷根 (美国商业资讯) — Harlan Laboratories, Ltd.是一家私有的提供商，通过其合同研究服务(CRS)业务，提供普通和专科毒理学服务，该公司已准备好满足新型生物制剂和生物类似物开发项目中的全球性需求。 在监管层对生物类似物的接纳方面，美国食品药品管理局(FDA)比欧洲药品管理局缓慢，尽管如此，Harlan...
View ArticleClik here to view.
ハーランが生物製剤とバイオシミラーの専門力を提供
スイス・イティンゲン （ビジネスワイヤ） — 受託研究サービス（CRS）事業を通じて一般的／専門的毒性検査サービスを提供する株式非公開企業のハーランラボラトリーズ・リミテッド（Harlan Laboratories, Ltd.）は、新規の生物製剤やバイオシミラーの開発プログラムに対する世界的な需要に対応できる体制にあります。...
View Article